

## ABBREVIATED CV

<b>NAME</b> Sasha Bernatsky	<b>POSITION TITLE</b>
	Associate Professor of Medicine

### EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
McGill University, Montreal, QC	PhD	2002-2005	Epidemiology & Biostatistics
McGill University, Montreal, QC	MSc	2000-2001	Epidemiology & Biostatistics
University of Manitoba, Winnipeg, MB		1999-2000	Community Health Studies
University of Manitoba, Winnipeg, MB		1996-1998	Rheumatology Fellowship
University of Western Ontario, London, ON		1993-1997	Internal Medicine Fellowship
University of Saskatchewan, Saskatoon, SK		1992-1993	Rotating Internship
University of Toronto, Toronto, ON	MD	1988-1992	Medicine
University of Saskatchewan, Saskatoon, SK	BSc	1985-1988	Physiology

### Honors and awards

Fonds de la recherche en santé du Québec Chercheurs-boursiers Junior	\$63,000 per annum	2010-2015
Canadian Rheumatology Association Young Investigator Award		2010
Lupus Foundation of America Mary Betty Stevens Young Investigator Award		2010
Canadian Arthritis Network: Consumer Research Award		2010
American College of Rheumatology (ACR) Dubois Plenary Presenter		2010
Junior Investigator Award, Canadian Institutes of Health Research (Career award)		2005-2010
Canadian Arthritis Network Scholar Award		2005
National Centres of Excellence Young Innovator Award		2005

### Research Network Memberships

Réseau de recherche en santé des populations du Québec	2010-2012
Réseau Québécois de recherche sur l'usage des médicaments.	2010-2012
Systemic Lupus International Collaborating Clinics (SLICC)	2005-2011
Canadian Network for Improved Outcomes in SLE	1998-2011
Canadian Arthritis Network (CAN)	1998-2011

### Selected first-author peer-reviewed publications

1. **Bernatsky S**, Rusu C, O'Donnell S, Mackay C\*, McRae L, Hawker G, et al. Self-Management Strategies in Overweight/Obese Canadians with Arthritis. *Arthritis Care Res (Hoboken)*. 2011 Oct 3. doi: 10.1002/acr.20654. [Epub ahead of print]
2. **Bernatsky S**, Linehan T, and Hanly JG. The Accuracy of Administrative Data Diagnoses of Systemic Autoimmune Rheumatic Diseases. *Journal of Rheumatology* 2011 Aug;38(8):1612-6.
3. **Bernatsky S**, Panopalis P, Pineau C, Hudson M, St. Pierre Y, and Clarke A. Health Care Costs of Inflammatory Myopathies. *J Rheumatol*. 2011 May;38(5):885-8.
4. **Bernatsky S**, Lix L, Hanly JG, Hudson M, Badley E, Peschken C, et al. Surveillance of Systemic Autoimmune Rheumatic Diseases Using Administrative Data. *Rheumatol Int*. 2011;31(4):549-54.
5. **Bernatsky S**, Peschken C, Fortin PR, Urowitz M, Gladman D, Pope J, Hudson M, Zummer M, Smith CD, Arbillaga HO, Clarke AE, CANIOS. Medication Use in Systemic Lupus. *J Rheumatol*. 2011;38(2):271-4.
6. **Bernatsky S**, Fournier M, Pineau CA, Clarke AE, Vinet E, Smargiassi A. Associations between Ambient Fine Particulate Levels and Disease Activity in SLE. *Environ Health Perspect*. 2011;119(1):45-9.
7. **Bernatsky S**, Feldman D, De Civita M, Haggerty J, Tousignant P, Legaré J. Optimal Care for Rheumatoid Arthritis: A Focus Group Study. *Clin Rheumatol*. 2010 Jun;29(6):645-57.
8. **Bernatsky S**, Ramsey-Goldman R, Gordon C, Clarke A. Short Report: Prostate Cancer in SLE. *International Journal of Cancer* 2011;129: 2966–2969.
9. **Bernatsky S**, Rosenberg A, Oen K, Duffy C, Ramsey-Goldman R, Labrecque J, St. Pierre Y and Clarke A. Malignancies in Juvenile Idiopathic Arthritis (JIA). *J Rheumatol*. 2011 Apr;38(4):760-3.

10. **Bernatsky S**, Clarke A. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus (SLE): A pooled analysis. *British Journal of Cancer* 2011;104: 1478-1481.
11. **Bernatsky S**, Youssef Habel, Rahme E. Observational Studies of Infections in Rheumatoid Arthritis: A Meta-analysis of the Effects of TNF Antagonists. *J Rheumatol.* 2010 May;37(5):928-31.
12. **Bernatsky S**, Renoux C\*, Suissa S. Demyelinating Events in Rheumatoid Arthritis. *Ann Rheum Dis.* 2010 Sep;69(9):1691-3.
13. **Bernatsky S**, Joseph L, Pineau CA, Lix L, Belisle P, Clarke AE. Polymyalgia Rheumatica Prevalence in a Population-based Sample. *Arthritis Care & Research* 2009;61:1264-1267.
14. **Bernatsky S**, Joseph L, Pineau CA, Belisle P, Boivin J-F, Banerjee D, Clarke AE. Estimating the Prevalence of Polymyositis and Dermatomyositis from Administrative Data: Age, Sex, and Regional Differences. *Annals of Rheumatic Diseases* 2009;68:1192-1196.
15. **Bernatsky S**, Panopolis P, Hudson M, Pope J, LeClercq, et al. Demographic and Clinical Factors Associated with Physician Service Use in Systemic Sclerosis. *J.Rheumatology* 2009;36(1):96-8.
16. **Bernatsky S**, Hudson M, Pope J, Markland J, Robinson D, Jones N, et al. Reports of Abnormal Cervical Cancer Screening Tests in Systemic Sclerosis. *Rheumatology* 2009;48(2):149-51.
17. **Bernatsky S**, Hudson M, Panopolis P, Clarke AE, Pope J, LeClercq S, et al. The Cost of Systemic Sclerosis. *Arthritis Rheum.* 2009;61(1):119-123.
18. **Bernatsky S**, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE. Scleroderma Prevalence: Demographic Variation in a Population-based Sample. *Arthritis Care & Research.* 2009;61:400-4.
19. **Bernatsky S**, Hudson M, Pope J, Vinet E, Markland J, Robinson D, et al. Assessment of Reproductive History of Systemic Sclerosis. *Arthritis Care and Research* 2008;59:1661-1664.
20. **Bernatsky S**, Ehrmann Feldman D. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Québec, Canada. *Drugs and Aging* 2008;25:879-84.
21. **Bernatsky S**, Boivin JF, Gordon C, Joseph L, Urowitz M, Gladman D, et al. The relationship between cancer and medication exposure in SLE. *Annals of Rheumatic Diseases* 2008;67(1):74-79.
22. **Bernatsky S**, Clarke AE, Suissa S. Hematological malignant neoplasms after drug exposure in rheumatoid arthritis. *Archives of Internal Medicine* 2008;168:378-381.
23. **Bernatsky S**, Clarke AE, Suissa S. Lung Cancer after Exposure to Disease Modifying Anti-Rheumatic Drugs. *Lung Cancer* 2008;59:266-269.
24. **Bernatsky S**, Joseph L, Pineau C, Tamblyn R, Feldman D, Clarke AE. A population-based assessment of SLE incidence and prevalence. *Rheumatology* 2007;46(12):1814-1818.
25. **Bernatsky S**, Hudson M\*, Suissa S. Anti-Rheumatic Drug Use and Risk of Serious Infections in Rheumatoid Arthritis. *Rheumatology* 2007;46(7):1157-60.
26. **Bernatsky S**, Souza R, de Jong K. Mental health in HIV-positive pregnant women: Results from Angola. *AIDS Care* 2007;19:674-676.
27. **Bernatsky S**, Ramsey-Goldman R, Isenberg D, Rahman A, Dooley MA, Sibley J, et al. Hodgkin's Lymphoma in Systemic Lupus Erythematosus. *Rheumatology* 2007;46:830-832.
28. **Bernatsky S**, Lee JL, Rahme E. Non-hodgkin's lymphoma: Meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. *Rheumatology* 2007;46(4):690-694.
29. **Bernatsky S**, Duffy C, Malleson P, Feldman DE, St. Pierre Y, Clarke AE. The economic impact of juvenile idiopathic arthritis. *Arthritis Rheum* 2007;57:44-48.
30. **Bernatsky S**, Clarke A, Gladman DD, Urowitz M, Fortin PR, et al. Mortality related to Cerebrovascular disease in SLE. *Lupus* 2006;5:835-839.
31. **Bernatsky S**, Feldman D, Shrier I, Toupin K, Haggerty J, Tousignant P, Zummer M. Care pathways in early rheumatoid arthritis. *Can Fam Physician* 2006;52:1444-1445.
32. **Bernatsky S**, Pineau CA, Lee JL, Clarke AE. Headache, Raynaud's syndrome, and serotonin receptor agonists in systemic lupus erythematosus. *Lupus* 2006;15(10):671-674.
33. **Bernatsky S**, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in Systemic Lupus Erythematosus. *Arthritis Rheum* 2006;54(8):2550-2557.
34. **Bernatsky S**, Cooper GS, Mill C\*, Ramsey-Goldman R, Clarke AE, Pineau CA. Cancer Screening in Patients with Systemic Lupus Erythematosus. *J Rheumatol* 2006;33(1):45-49.

**Ongoing Research Support**

- CIHR Abrahamowicz (PI)** 2011 – 2016 **Canadian Institutes of Health Research**  
New Statistical Methods for Population-based Studies of Comparative Effectiveness and Safety of Medications: Development, Validation and Applications **Role:** Co-PI  
Objective: To optimize statistical methods for comparative effectiveness research
- CIHR Abrahamowicz (PI)** 2011 – 2016 **Canadian Institutes of Health Research**  
Developing Advanced Methods for Population-Based Comparative Effectiveness Studies **Role:** Co-investigator  
Objective: To optimize statistical methodology for studies of comparative drug effectiveness and safety
- CIHR Tamblyn (PI)** 2011 – 2015 **Canadian Institutes of Health Research**  
Evaluating the Accuracy of New Methods of Pharmasurveillance: Computerized Administrative Data and Electronic Prescribing and Drug Management Systems **Role:** Co-investigator  
Objective: To evaluating the accuracy of novel pharmasurveillance methodology
- CIHR Hemmelgarn (PI)** 2011 – 2014 **Canadian Institutes of Health Research**  
Arthritis in First Nations People in Alberta: Prevalence and Health Care Utilization **Role:** Co-investigator  
Objective: To estimate the prevalence of arthritis in First Nations people in Alberta
- CIHR Bernatsky (PI)** 2011 – 2013 **Canadian Institutes of Health Research**  
Obstetrical Complications and Long-term Outcomes for Children Born to Women with SLE **Role:** PI  
Objective: To assess obstetrical complications and long-term outcomes in children born to mothers with SLE
- CIHR Bernatsky (PI)** 2011 – 2012 **Canadian Institutes of Health Research**  
Exercise in Rheumatic Disease **Role:** PI  
Objective: To disseminate knowledge about exercise in rheumatic disease
- CFI Baron (PI)** 2010 – 2013 **Canada Foundation for Innovation**  
McGill Systemic Autoimmune Rheumatic Diseases (SARD) **Role:** Co-investigator  
Objective: To harmonize variables across SARD research databases.
- CIHR Bernatsky (PI)** 2010 – 2011 **Canadian Institutes of Health Research**  
Surveillance of Chronic Rheumatic Diseases Using Administrative Databases. **Role:** PI  
This funding supports KTE activities regarding the use of administrative data for rheumatic disease research.
- CIHR Bernatsky (PI)** 2010 – 2013 **Canadian Institutes of Health Research**  
Cancer Risk in Pediatric-onset Rheumatic **Role:** PI  
Objective: To assess cancer risk in pediatric-onset rheumatic diseases.
- 200605ITM-162349-HTI-CFAC-61889 Bernatsky (PI)** 2009 –2011 **Canadian Arthritis Network**  
Administrative Database Research in Rheumatic Diseases: Pediatric Populations **Role:** PI  
Objective: To assess rheumatic disease prevalence in pediatric populations.
- PHAC 6271-15-2008/3970725 - Bernatsky (PI)** 2009 –2011 **Public Health Agency of Canada**  
Validation of disease case definitions based on administrative data. **Role:** PI  
Objective: To use clinical datasets to confirm rheumatic disease case definitions found in administrative data.
- CIH 177821 Rahme (PI)** 2008–2012 **Canadian Institutes of Health Research**  
Risk-benefit ratio of extended thromboprophylaxis ... **Role:** Co-Investigator  
Objective: To evaluate and compare the outcomes venothromboemboli and bleeding associated with thromboprophylaxis administered after discharge for patients who underwent total hip or knee replacement
- MOH Bombardier (PI)** 2008-2011 **Ontario Ministry of Health**  
Effectiveness & optimal use of biologic response modifying drugs for rheumatoid arthritis **Role:** Co-PI  
Objective: To assess the use of biologic drugs in rheumatoid arthritis.
- CIHR Siminovitch (PI)** 2007-2012 **Canadian Institutes of Health Research**  
Determinants of risk and outcome in inflammatory arthritis **Role:** Co-PI